Avalo shares are trading higher after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.
Benzinga Newsdesk - Mar 28, 2024, 9:08AM